New Treatments Emerge for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

DataM Intelligence has released an analysis of treatments for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), a rare neurological disorder characterized by inflammation and damage to peripheral nerves and nerve roots. The condition affects approximately 1 to 7 adults per 100,000, though underreporting is suspected.

Treatment strategies for CIDP primarily focus on modulating the immune response. Current first-line therapies include corticosteroids, intravenous immunoglobulin (IVIg), and plasma exchange. A significant development in June 2024 was the US Food and Drug Administration's (FDA) approval of Vyvgart® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) for adult patients with CIDP.

The pipeline for CIDP treatments is active, with multiple new therapies, including monoclonal antibodies and immunoglobulins, targeting various disease mechanisms. Vyvgart Hytrulo offers a novel mechanism of action and a convenient subcutaneous administration, potentially improving patient adherence and experience. Other established and emerging treatments include Takeda's HYQVIA and GAMMAGARD LIQUID, CSL Behring's Hizentra, and Pfizer's Panzyga.

The competitive landscape for CIDP treatments is expanding. The introduction of new therapeutic options alongside existing ones aims to improve patient outcomes and quality of life. DataM Intelligence's analysis highlights the growing market, driven by therapies offering different administration routes and mechanisms to address unmet needs in managing this rare condition.